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Abstract
Purpose Multi-parametric magnetic resonance imaging (MP-
MRI) is currently the most comprehensive work up for non-
invasive primary tumor staging of prostate cancer (PCa).
Prostate-specific membrane antigen (PSMA)-Positron emis-
sion tomography–computed tomography (PET/CT) is pre-
sented to be a highly promising new technique for N- and
M-staging in recurrent PCa-patients. The actual investigation
analyses the potential of 68Ga-PSMA11-PET/CT to assess the
extent of primary prostate cancer by intra-individual compar-
ison to MP-MRI.
Methods In a retrospective study, ten patients with primary
PCa underwent MP-MRI and PSMA-PET/CT for initial stag-
ing. All tumors were proven histopathological by biopsy.
Image analysis was done in a quantitative (SUVmax) and
qualitative (blinded read) fashion based on PI-RADS. The
PI-RADS schema was then translated into a 3D-matrix and
the euclidian distance of this coordinate system was used to
quantify the extend of agreement.
Results Both MP-MRI and PSMA-PET/CT presented a good
allocation of the PCa, which was also in concordance to the
tumor location validated in eight-segment resolution by biop-
sy. An Isocontour of 50% SUVmax in PSMA-PET resulted in
visually concordant tumor extension in comparison to MP-
MRI (T2w and DWI). For 89.4 % of sections containing a
tumor according to MP-MRI, the tumor was also identified in
total or near-total agreement (euclidian distance ≤1) by
PSMA-PET. Vice versa for 96.8 % of the sections identified
as tumor bearing by PSMA-PET the tumor was also found in
total or near-total agreement by MP-MRI.
Conclusions PSMA-PET/CT and MP-MRI correlated well
with regard to tumor allocation in patients with a high pre-
test probability for large tumors. Further research will be need-
ed to evaluate its value in challenging situation such as pros-
tatitis or after repeated negative biopsies.
Keywords Prostate cancer . PSMA .Multi-parametricMRI .
T-staging
Introduction
Initial prostate cancer staging is an important diagnostic pro-
cedure for patient stratification. During the last years, non-
invasive multi-parametric magnetic resonance imaging has
been introduced and clinically well established for T-staging
in prostate cancer patients [1]. Multi-parametric magnetic res-
onance imaging (MP-MRI) includes several different MR-se-
quences, i.e., T2w, DW, DCE-MRI and MRS. Due to a very
high imaging data volume, reporting standards such as PI-
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RADS were introduced to harmonize image analysis and im-
prove patient staging outcome [2].
Recently, prostate-specific membrane antigen (PSMA)-
Positron emission tomography–computed tomography (PET/
CT) based on the ligand 68Ga-PSMA11 has shown the poten-
tial to improve the detection of metastatic spread of prostate
cancer in patients with biochemical recurrence [3, 4]. In this
setting, PSMA-PET/CT was found superior in comparison to
contrast-enhanced CT [5, 6] and Choline-PET/CT [7] with
regard to lymph node involvement and detection of distant
metastases. Phase-I/II data found PSMA-SPECT/CT with
99mTc-trofolastat (MIP-1404) is also promising for diagnostics
of primary PCa [8]. In contrast, data for T-staging with
PSMA-PET/CT have not been reported as of yet. Thus, MRI
is still considered as the gold standard for T-Staging of PCa,
due to the fact of detailed depiction of size, infiltration and
adjacent organ involvement [1, 2].
This retrospective study aimed to quantify the agreement of
multi-parametric MRI and PSMA-PET/CT in T-Staging.
Material and methods
Patients
This is a retrospective analysis of ten patients scheduled for
primary radiotherapy of their PCa who received both
multiparametric magnetic imaging and PSMA-PET/CT imag-
ing. External beam radiotherapy of localized prostate cancer is
not inferior to radical prostatectomy [9]. For this collective of
patients, imaging of primary PCa is of high clinical impact for
defining the target volume of radiotherapy. In contrast, surgery
candidates rarely benefit from improved local imaging; thus,
we were not able to include surgery patients who would allow
a better correlation to histopathology.
The median age was 70 years (range 61–74) with a median
Gleason score (GSC) of 8 (range 7b–9) and a median prostate-
specific antigen (PSA) level of 15 ng/ml (range 9.92–36.2).
According to the D'Amico criteria, all ten patients had a high-
risk cancer. Table 1 summarizes the characteristics of the ex-
amined patient cohort. The evaluation was done with approval
of our local ethic committee (S-321). All patients signed a
written informed consent form for the purpose of anonymized
evaluation and publication of their data.
PET/CTwith 68Ga-PSMA11
PSMA-PET/CT was performed on a Biograph 6 PET/CT
scanner (Siemens, Erlangen, Germany) 60 ± 10 min after
intravenous inject ion of 68Ga-PSMA11 (median
179 MBq, range 121–240 MBq). 68Ga-PSMA11 was syn-
thesized as previously described [10]. First, a CT scan
(130 keV, 80 mAs; CareDose) without contrast medium
was performed. Static emission scans, corrected for dead
time, scatter and decay were acquired from the vertex to
the proximal legs, requiring eight bed positions with
3 min per bed position. The images were iteratively re-
constructed including CT-based attenuation correction
with the OSEM algorithm using four iterations with eight
subsets and Gaussian filtering to an in-plane spatial reso-
lution of 5 mm at full-width at half-maximum. For calcu-
lation of the standardized uptake value (SUV), circular
regions of interest were drawn around the area with focal-
ly increased uptake in transaxial slices and automatically
adapted to a three-dimensional volume of interest with
e.soft software (Siemens) at a 50 % isocontour.
Multiparametric MRI
Magnetic resonance imaging was performed using T2w (TR:
5.68 ms, TE 84 ms, Matrix: 512×384), DWI (TR 2.806 ms,
TE 75 ms, Matrix: 128×128, b-value 50, 400, 800 s/mm2),
apparent diffusion coefficient (ADC)-map and T1w contrast
enhanced MRI (FLASH 3D FS, TR 3.68 ms, TE 1.29 ms,
Matrix 384×238) at 1.5 Tesla.
Histopathological evaluation
The urologist/pathologist reported core biopsy with an eight-
segment resolution. Reported as left/right lobe, basal/ apical
level and central/ peripheral zone.
Blind read and statistical analysis
Two experienced readers (CK and HS) staged the tumor
extension in the prostatic gland based on the PI-RADS
scheme (Fig. 1a). For further statistical analysis, each sec-
tor of the PI-RADS scheme was represented in a three-
dimensional coordinate system (x,y,z), with x representing
the left/right orientation of the segment (from 1 to 4), y
Table 1 Patient characteristics of the analyzed cohort






1 71 high-risk 9 13.8 8.2 5.9
2 74 high-risk 8 16.2 25.4 19.3
3 65 high-risk 7b 35.7 20.9 15.7
4 72 high-risk 9 9.62 18.5 13.8
5 70 high-risk 6 31.8 7.8 5.9
6 64 high-risk 7b 93 22.1 16.1
7 61 high-risk 7b 36.17 33.4 23.1
8 73 high-risk 9 14.4 54 39
9 68 high-risk 8 13.3 14 10
10 70 high-risk 8 15.7 21.3 17.2
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representing the position on the dorsoventral axis (from 1
to 3) and z representing the four different layers of apex,
mid, base and semilunar vesicles (SV) (as 1–4). As there
is only one central segment each in the ventral regions
(13as/14as/15as), this segment has been assigned an x
value of 2.5 to indicate its equal proximity to the adjacent
x = 2 and x = 3 segments (Fig. 1b). Thus, for example,
segment 9a is the third segment from the left, the second
from the front, and on the second layer (mid), and is thus
classified as (3-2-2), while 13as is classified as (2.5-3-3).
As SV includes only a single section that is not adjacent
to any other and infiltration of SV directly changes T-
stage, we classified this segment as (0-0-4).
As neither of the two methods compared here is a definite
gold standard, we consider two different analyses: First, we
investigate what proportion of the sections identified by MP-
MRI was also found in the PSMA-PET (MRI→PET), and
second, what proportion of sections identified by PSMA-
PETwas also found by MP-MRI (PET→MRI). As an exam-
ple, a result of (100/100 %) would indicate a perfect agree-
ment, while a result of (100/50 %) would indicate that while
the PSMA-PET confirmed all of the affected regions from the
MP-MRI, it also identified twice the number of affected re-
gions in total.
For both comparisons, we also performed a secondary
analysis allowing partial agreement in the previous anal-
ysis. Partial agreement for an affected section was con-
sidered to be achieved if the second method identified
either exactly the same section or a directly adjacent
section (mathematically: Euclidian distance on the x,y,z
coordinate system is one or less). Note that sections
dislocated by one on two or more of the axes simulta-
neously were not considered to be adjacent (i.e., 3A is
not adjacent to 9P).
PI-RADS
3-dimensional coding for 
quantification of agreement 
a
Fig. 1 a: Blinded read evaluation according to PI-RADS and three-
dimensional coding for quantification of agreement. The left figure
presents the prostate regions as defined by PI-RADS, while the right
figure visualizes our numerical coding for the three-dimensional
position of these regions. b: The two figures present an example of an
affected area in the prostate gland with near-total (upper row) and total
(low row) agreement. In the upper row, all MRI-positive regions (section
2-1-2 only) were also found by PSMA-PET, while only half the PSMA-
PET positive regions were identified identically in MRI. Thus, the total
agreement score is 100/50 %. Regarding the section 1-1-2 missing in the
MRI, an adjacent section (2-1-2) was identified by the MRI, so this is
counted as a near-total agreement. Thus, the near-total agreement score is
100/100 %. In the lower row, all sections were identified identically by
both methods; therefore, both agreement scores are 100/100 %
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Results
All ten patients have been evaluated by the two-blinded
readers based on MP-MRI and PSMA-PET/CT, respectively.
Themedian SUVmaxwas 21.1 (range: 8.2–33.4) in the cancer
affected area of the prostate gland according to the biopsy.
In comparison to the histological gold standard, both mo-
dalities found the main tumor mass in the location of the core
biopsy containing the highest percentage of tumor involve-
ment and Gleason score. As the Bresolution^ of tissue sam-
pling in biopsy (eight segments—left/right, basal/apical, cen-
tral/peripheral) is below the resolution of diagnostic imaging,
histopathology could not serve as gold standard for tumor
extension.
Despite the perfect concordance in eight-segment resolu-
tion, the tumor extent scored by the blinded readers using the
PI-RADS schema presented some mismatch in 50 % of the
cases (n=10 patients); Fig. 2. The total agreement rates based
on segment analysis (n=270 segments) were MRI→PET
63.5 % (SD 31.1 %) and PET→MRI 80.2 % (SD 31.2 %),
i.e., a bit more than three-fifths of the affected segments found
in MP-MRI were also identically found in PSMA-PET, while
four-fifths of the segments found in PSMA-PET were also
found in MP-MRI.
Near-total agreement rates were MRI→PET 89.4 % (SD
14.3%) and PET→MRI 96.8% (SD 7.1%), i.e., in most cases
for sections identified in one method, at least an adjacent sec-
tion was identified by the other method. Only about 11 % of
sections identified in MP-MRI could not be identified at all in
PSMA-PET, and about 3 % of PSMA-PET results could not
be confirmed at all in MP-MRI. Note that in five of the ten
patients, a perfect agreement was achieved between both
methods, including one patient with total agreement with re-
gard to suspicious semilunar vesicle infiltration (Fig. 3).
Discussion
We evaluated the potential of 68Ga-PSMA11-PET/CT for im-
aging primary PCa by intra-individual comparison to MP-
MRI. As shown recently, PSMA-PET/CT has considerable
impact on the radiotherapeutic management of prostate cancer
patients [5]. Sensitive and specific imaging is a fundamental
condition for definition of the target volume in radiotherapy.
For example, radiation oncology aims to escalate dose to areas
of high tumor cell burden and/or radiation resistance. Thus,
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under clinical investigation to enable individualized aggres-
sive treatment based on personalized risk assessment [11].
Based on the eight-segment resolution of biopsy, MP-MRI
and PSMA-PET/CT presented identical tumor allocations.
However, these good results might have been supported by
patient selection, which were all Bhigh-risk^ with a high prob-
ability for large T3/4 tumors. Nevertheless, according to the
established 27-segment PI-RADS (V1) schema, total agree-
ment was only found in 5/10 patients. However, the formally
discrepant findings revealed to be near-total findings using the
Euclidian distance to quantify translocation. Different ana-
tomical landmarks delineable on CT and MRI might be one
explanation, the higher in plane spatial resolution of MRI in
comparison to PET, another. Nevertheless, measuring the ex-
act tumor extension is a general challenge in PCa. PCa com-
monly presents with a mixture of different gradings simulta-
neously within one lesion as well as multi-locally. Blurred
lesion borders appear due to a diffuse infiltrative growth.
These challenges are present even microscopically, leading
to recent revisions on the pathological classification criteria
[12]. In analogy, amongst different MRI sequences, the mea-
sured lesion size can differ, e.g., hot-spots with strong
diffusion restriction on DWI (Fig. 2d) are commonly
interpreted to be tightly packed, cell-rich sub-areas within
the tumor, but their extent can be significantly lower than
the tumor size delineable in contrast enhanced T1w
(Fig. 2b). In a similar manner, PSMA-PET might underesti-
mate the total tumor extension. High PSMA expression is
significantly correlated with higher Gleason score [13].
Thus, PET might highlight only poorly differentiated sub-
volumes within the tumor, which might underestimate gross
tumor diameter, but vice versa could be beneficial with regard
to the described Bdose painting^ concepts in radiation therapy.
However, this thesis has to be proven in the future. Another
critical aspect that did not yet become apparent in our study is
the possibility of PSMA negative tumor phenotypes, which
have been reported with a probability of about 10 % in recur-
rent prostate cancers [3, 4]. Robust data for newly diagnosed
PCa are still pending.
The increasingly available of PET/MRI hybrid scanners
might be suitable to combine the molecular information de-
rived from PSMA-PETwith the higher resolution and anatom-
ical landmark definition derived fromMRI. This novel gener-





Fig. 2 Example for a near-total agreement. Biopsy proven prostate
cancer in the right, peripheral zone. In MP-MRI, a signal drop in T2w
(a), fast wash-out in contrast enhanced T1w sequence (b), focal diffusion
restrictions in DWI (d) and corresponding ADC-map (e) were interpreted
as tumor infiltration of segment 4P. On a visual basis, the PSMA-PET (c)
presents a very similar tumor extent, but was scored as tumor spread into
the segments 4A and 4P
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tumors (T-stage) by MP-MRI, while N- and M-staging can
simultaneously be improved with PSMA-PET (Fig. 4).
In conclusion, PSMA-PET/CT and MP-MRI correlated
well in tumor allocation in patients with a high pre-test
probability for large tumors. Further research will be needed
to evaluate the advantages of PSMA-PET/CT in challenging
situations (e.g., prostatitis, benign prostate hyperplasia or after
repeated negative biopsies) or if patients truly benefit from the
a b c
d e
Fig. 4 A 61-year-old patient with a biopsy-proven prostate cancer in the
left peripheral zone. According toMP-MRI (a, T2w; c, CE-T1w; d, DWI,
e, ADC), the tumor affected PI-RADS segments 9Pand 10P. In PSMA-
PET (b, red arrow), a near-total agreement (tumor affecting PI-RADS
segments 9P, 10P and 10A) was scored. PSMA-PET also diagnosed a
loco-regional lymph node metastasis (b, yellow arrow) that was
retrospectively also delineable in CE-T1w (c), DWI (d) and ADC (e)
a b c
d e f
Fig. 3 A68-year-old patient presented a large extension of tumormass in
the base of the prostate gland with infiltration of the semilunar vesicles. In
MP-MRI, this presents with a signal drop in T2w sequence (a, sagittal
view; b, axial view), contrast enhancement in T1w sequence (f) and
diffusion restriction, as demonstrated in the ADC map (c). PSMA-PET
(d, sagital view; e, axial view) presentedwith corresponding tumor spread
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handling of PSMA-positive findings as dominant intra-
prostatic lesions during radiation therapy.
Compliance with ethical standards All procedures performed in stud-
ies involving human participants were in accordance with the ethical
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the 1964 Helsinki declaration and its later amendments.
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